Chemed Corporation (NYSE:CHE) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Chemed Corporation (NYSE:CHE) have earned a consensus rating of “Hold” from the six ratings firms that are covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $501.50.

Several research analysts have recently weighed in on the stock. Oppenheimer dropped their target price on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Wall Street Zen downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research report on Monday. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Royal Bank Of Canada boosted their price objective on shares of Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research report on Monday, April 27th. Finally, Weiss Ratings raised shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th.

Chemed Stock Performance

Chemed stock opened at $446.85 on Wednesday. The firm’s 50 day simple moving average is $412.34 and its 200-day simple moving average is $424.66. The company has a market cap of $5.93 billion, a P/E ratio of 24.35, a price-to-earnings-growth ratio of 1.65 and a beta of 0.54. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.85 and a quick ratio of 0.83. Chemed has a fifty-two week low of $365.20 and a fifty-two week high of $562.77.

Chemed (NYSE:CHE) last released its earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share for the quarter, topping the consensus estimate of $5.30 by $0.35. The business had revenue of $657.51 million for the quarter, compared to the consensus estimate of $659.22 million. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period last year, the firm posted $5.63 earnings per share. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. As a group, equities research analysts predict that Chemed will post 22.3 EPS for the current year.

Chemed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Investors of record on Thursday, May 28th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, May 28th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed’s payout ratio is presently 13.08%.

Insider Buying and Selling

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the transaction, the chief executive officer directly owned 90,219 shares of the company’s stock, valued at approximately $37,993,927.47. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 3.33% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Maripau Wealth Management LLC grew its position in Chemed by 5.4% during the first quarter. Maripau Wealth Management LLC now owns 970 shares of the company’s stock valued at $366,000 after purchasing an additional 50 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in Chemed in the first quarter valued at approximately $2,293,000. Cim LLC lifted its stake in Chemed by 1.6% in the first quarter. Cim LLC now owns 2,325 shares of the company’s stock valued at $878,000 after acquiring an additional 37 shares during the last quarter. Amundi lifted its stake in Chemed by 6,982.7% in the first quarter. Amundi now owns 35,555 shares of the company’s stock valued at $13,431,000 after acquiring an additional 35,053 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in Chemed by 9.4% in the first quarter. EverSource Wealth Advisors LLC now owns 406 shares of the company’s stock valued at $153,000 after acquiring an additional 35 shares during the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.